companydata.dkcompanydata.dk

Scantox Ballerup ApS: Financial statements 2024

CVR: 34724938

Source: annual report 2024, Danish Business Authority

01/01/2024 – 31/12/2024

Scantox Ballerup ApS (CVR 34724938) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 18,716,457 and a net result of DKK 255,010 compared with DKK 1,070,172 the year before. That is an increase of 67.1% compared with the year before. Equity in the 2024 report amounted to DKK 391,373. The solvency ratio was 3.2%. The company had 20 employees in the financial year.

Gross Profit
DKK 18,716,457
Profit/Loss
DKK 255,010
Equity
DKK 391,373
Total Assets
DKK 12,175,169
Employees
20

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024-18.7M255K391K20
2023-11.2M1.1M7M11
2022-14.1M4.7M10M9
2021-9.6M2.3M7.1M8
2020-6.3M287K5M7

Official annual report

View the official annual report directly on the page with a Pro subscription.

Screen every Danish company

Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.

Try company screening

Events in 2024

SOLURAL PHARMA ApS changes name to Scantox Ballerup ApSOct 28, 2024

On October 28, 2024, the company changed its name from SOLURAL PHARMA ApS to Scantox Ballerup ApS.

Scantox Ballerup ApS appoints new auditorSep 3, 2024

As of September 3, 2024, EY Godkendt Revisionspartnerselskab has been appointed auditor of Scantox Ballerup ApS.

Auditor steps down at Scantox Ballerup ApSSep 3, 2024

As of September 3, 2024, NEJSTGAARD & VETLOV, GODKENDT REVISIONSAKTIESELSKAB has stepped down as auditor of Scantox Ballerup ApS.

Scantox Ballerup ApS: The 2023 annual report is outJun 17, 2024

Scantox Ballerup ApS has published its annual report for 2023. Gross profit came to DKK 11,201,034, and the net result was DKK 1,070,172.

About Scantox Ballerup ApS

Scantox Ballerup ApS is a Danish company of the type Anpartsselskab based in Ballerup, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named SOLURAL PHARMA ApS. The management consists of Helle Kirstein Erichsen. The board consists of Jeanet Løgsted Nielsen (chair) and Emil Staal Bergander. The company is owned by Scantox Denmark ApS. The company has 14 employees (2026). In 2025, the company reported a gross profit of DKK 13,349,106 and a net result of DKK -1,931,049 compared with DKK 255,010 the year before. Equity in the 2025 report amounted to DKK -1,539,321.

Source: annual report 2025, Danish Business Authority